Wells Fargo
FDMT icon

Wells Fargo’s 4D Molecular Therapeutics FDMT Stock Holding History

Wells Fargo’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$170K Sell
18,309
-28,311
-61% -$246K ﹤0.01% 4801
2025
Q4 		$350K Buy
46,620
+15,631
+50% +$159K ﹤0.01% 4733
2025
Q3 		$269K Buy
30,989
+5,022
+19% +$30K ﹤0.01% 4752
2025
Q2 		$96.3K Buy
25,967
+2,313
+10% +$8.13K ﹤0.01% 5212
2025
Q1 		$76.4K Sell
23,654
-2,198
-9% -$10.4K ﹤0.01% 5235
2024
Q4 		$144K Buy
25,852
+7,463
+41% +$58.6K ﹤0.01% 4985
2024
Q3 		$199K Buy
18,389
+144
+0.8% +$2.39K ﹤0.01% 4587
2024
Q2 		$383K Buy
18,245
+3,900
+27% +$97.8K ﹤0.01% 4080
2024
Q1 		$457K Buy
14,345
+2,071
+17% +$52.8K ﹤0.01% 3953
2023
Q4 		$249K Sell
12,274
-19,821
-62% -$261K ﹤0.01% 4332
2023
Q3 		$409K Sell
32,095
-6,988
-18% -$117K ﹤0.01% 3906
2023
Q2 		$706K Buy
39,083
+11,095
+40% +$204K ﹤0.01% 3707
2023
Q1 		$481K Buy
27,988
+27,788
+13,894% +$540K ﹤0.01% 3873
2022
Q4 		$4.44K Sell
200
-69
-26% -$1.07K ﹤0.01% 5810
2022
Q3 		$3K Sell
269
-279
-51% -$2.53K ﹤0.01% 6048
2022
Q2 		$3K Sell
548
-10,531
-95% -$102K ﹤0.01% 6174
2022
Q1 		$168K Sell
11,079
-9,155
-45% -$144K ﹤0.01% 5081
2021
Q4 		$444K Buy
20,234
+12,550
+163% +$308K ﹤0.01% 4758
2021
Q3 		$206K Buy
7,684
+6,859
+831% +$196K ﹤0.01% 5081
2021
Q2 		$20K Sell
825
-1,615
-66% -$49.4K ﹤0.01% 5896
2021
Q1 		$106K Buy
+2,440
New +$108K ﹤0.01% 5452

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wells Fargo's FDMT Position: Q1 2026 in Review

Wells Fargo reduced its 4D Molecular Therapeutics (FDMT) stake by 61% in Q1 2026, selling an estimated $246K and leaving 18,309 shares worth $170K. The position accounts for ﹤0.01% of the portfolio, ranked #4801.

Wells Fargo first reported a position in FDMT in Q1 2021 and has held it in 21 quarters since. The position peaked at $706K in Q2 2023. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Wells Fargo held 18,309 shares of 4D Molecular Therapeutics worth $170K as of Q1 2026.
  • Wells Fargo sold 28,311 4D Molecular Therapeutics shares in Q1 2026, an estimated $246K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4801 holding.
  • Wells Fargo first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Wells Fargo's 4D Molecular Therapeutics position peaked at $706K in Q2 2023.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.